anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention aims to provide a highly-efficient culture technology, which can improve the biological conversion efficiency of sparassia crispa(Wulf.)Fr., shorten a production cycle and effectively reduce the production cost. The technology comprises the following steps of: (a) the preparation of a mother culture, (b) the preparation of a stock culture preparation, (c) the preparation of cultivated species, (d) the preparation of a culture pocket, (e) high-pressure intermittent sterilization, (f) inoculation, (g) variable temperature cultivation, (h) fruiting management, (i) harvesting, (j) grading and (k) packaging. In the highly-efficient culture technology, a mother culture medium formula and an inoculation way are innovatively improved, and a two-pint inoculation method and the improved mother culture medium formula are adopted to greatly shorten the growth time of hyphae and increase the amount of growth of the hyphae; high-pressure intermittent blow-off sterilization treatment is performed on the raw materials; an improved culture medium formula and a hypha variable temperature culture method are adopted; a one-step production and fruiting method is adopted; and when used for culturing sparassia crispa(Wulf.)Fr. fruit bodies, the highly-efficient culture technology ensures short culture cycle, high commodity rate and high biological conversion rate, and reduces the sparassia crispa(Wulf.)Fr. culturing cost.
A method for producing foams containing biological materials is described. A solid or semi-solid paste is formed by combining biologically active material with a protecting agent in an aqueous solvent. The paste formed is allowed to set, and may optionally then be apportioned into the desired shape. The paste may be frozen to allow formation of ice crystals to act as porogens. Subsequently, the paste is exposed to travelling wave radiant energy under vacuum (t-REV) for drying. This causes the solvent to boil off, leaving dried material containing the biologically active material, the protecting agent, and a relatively low water content. Biologically active materials which can be used include cells, microbial cultures, live attenuated microbes, probiotics, yeasts, enzymes, vaccines, proteins, and any heat-sensitive biological material. By directing energy via a travelling wave through a sample, good control of temperature and process conditions can be achieved. The method provides an alternative to the conventional methods of particulate leaching or freeze drying.
Diabetes mellitus is a devastating chronic metabolic disease. Since the majority of type 2 diabetes mellitus patients are overweight or obese, a novel term-diabesity-has emerged. The gut-brain axis plays a critical function in maintaining glucose and energy homeostasis and involves a variety of peptides. Amylin is a neuroendocrine anorexigenic polypeptide hormone, which is co-secreted with insulin from β-cells of the pancreas in response to food consumption. Aside from its effect on glucose homeostasis, amylin inhibits homeostatic and hedonic feeding, induces satiety, and decreases body weight. In this narrative review, we summarized the current evidence and ongoing studies on the mechanism of action, clinical pharmacology, and applications of amylin and its analogs, pramlintide and cagrilintide, in the field of diabetology, endocrinology, and metabolism disorders, such as obesity.
The recommended adult oral dosage for active benign gastric ulcer is 40 mg once a day at bedtime. Acute Therapy:

Gastroesophageal Reflux Disease (GERD)

The recommended oral dosage for treatment of adult patients with symptoms of GERD is 20 mg b.i.d. for up to 6 weeks. The recommended oral dosage for the treatment of adult patients with esophagitis including erosions and ulcerations and accompanying symptoms due to GERD is 20 or 40 mg b.i.d. for up to 12 weeks (see , ). CLINICAL PHARMACOLOGY IN ADULTSClinical Studies
Warning coloration and Batesian mimicry are classic examples of Darwinian evolution, but empirical evolutionary patterns are often paradoxical. We test whether foraging costs predict the evolution of striking coloration by integrating genetic and ecological data for aposematic and mimetic snakes (Elapidae and Dipsadidae). Our phylogenetic comparison on a total of 432 species demonstrated that dramatic changes in coloration were well predicted by foraging strategy. Multiple tests consistently indicated that warning coloration and conspicuous mimicry were more likely to evolve in species where foraging costs of conspicuous appearance were relaxed by poor vision of their prey, concealed habitat, or nocturnal activity. Reversion to crypsis was also well predicted by ecology for elapids but not for dipsadids. In contrast to a theoretical prediction and general trends, snakes' conspicuous coloration was correlated with secretive ecology, suggesting that a selection regime underlies evolutionary patterns. We also found evidence that mimicry of inconspicuous models (pitvipers) may have evolved in association with foraging demand for crypsis. These findings demonstrate that foraging is an important factor necessary to understand the evolution, persistence, and diversity of warning coloration and mimicry of snakes, highlighting the significance of additional selective factors in solving the warning coloration paradox.
Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
Sacral nerve stimulation (SNS) is a well-established treatment for refractory urinary urgency, frequency, retention and urge incontinence as well as fecal incontinence. Patients whose symptoms are refractory to more conservative therapies such as behavioral modification and/or medications are candidates for SNS. The InterStim system consists of a permanent tined lead and implantable pulse generator (IPG) or battery that delivers the sacral neuromodulation. This device is typically implanted after patients have a successful response to a trial of sacral neuromodulation with a temporary lead and external battery. The temporary lead placement is known as a Percutaneous Nerve Evaluation (PNE) and is typically done in as an outpatient procedure using local anesthetic. It is standard practice to use fluoroscopy intraoperatively to confirm correct placement of the permanent lead. Additionally, some physicians also use fluoroscopy to confirm correct placement of temporary lead during PNE while others place the lead based on anatomical landmarks and expected elicited responses for S3 stimulation.

The investigators propose a randomized control trial comparing the rate of implantation of the InterStim device following (PNE) performed with or without fluoroscopic guidance.
Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
BACKGROUND: Although a non-drainage procedure following total knee arthroplasty (TKA) is becoming more acceptable in enhanced recovery after surgery, postoperative drainage is still commonly used in TKA surgeries. This study aimed to compare the non-drainage to the drainage during the early postoperative stage regarding proprioceptive and functional recovery, and postoperative outcomes of TKA patients.
MATERIAL AND METHODS: A prospective, single-blind, randomized, controlled trial was carried out on 91 TKA patients, who were randomly allocated into the non-drainage group (NDG) or the drainage group (DG). Patients were evaluated regarding knee proprioception, functional outcomes, pain intensity, range of motion, knee circumference, and anesthetic consumption. Outcomes were assessed at the time of charge, at postoperative 7th day, and at postoperative 3rd month.
RESULTS: There were no differences between groups at baseline (p > 0.05). During the inpatient period, the NDG experienced superior pain relief (p < 0.05), had a higher Hospital for Special Surgery knee score (p = 0.001), demanded lower assistance from a sitting position to a standing position (p = 0.001) and walking for 4.5 m (p = 0.034), and performed the Timed Up and Go test in a shorter duration (p = 0.016) compared to the DG. The NDG gained the actively straight leg raise earlier (p = 0.009), needed lower anesthetic consumption (p < 0.05), and showed improved proprioception (p < 0.05) compared to the DG during the inpatient period.
CONCLUSIONS: Our findings support that a non-drainage procedure would be a better option to provide a faster proprioceptive and functional recovery, and beneficial results for patients following TKA. Therefore, the non-drainage procedure should be the first choice in TKA surgery rather than drainage.
Vaccination controls will undergo two CMR examinations. The scans will take place (i) within 2 weeks before received 1st dose of COVID-19 vaccine and (ii) within 2 weeks (preferably 5-7 days) after receiving the 2nd dose of COVID-19 vaccine. At time of CMR examinations, patients will have blood tests.
The aim of the study is the evaluation of the effectiveness, tolerance and cosmetic acceptability of Bariéderm cream among patients presenting with chronic allergic or irritant contact dermatitis of the hands. We shall enrol adults presenting with CONTACT DERMATITIS EXCLUDING FLARE-UPS of the hands: whether allergic or irritant, able to understand the protocol and agrees to sign the information and informed consent form. Bariéderm cream will be applied minimum twice daily over 21 days. Response will be evaluated by self and physician filled questionnaires. effectiveness, tolerance and cosmetic acceptability will be evaluated by a scale of 1-10, 1 meaning "not at all" and 10 meaning "very much". Statistics will be performed by SPSS software with suitable statistical tests. In case of an adverse event caused by the product, patch-test with ingredients of Bariéderm cream will be performed.
This randomized (patients assigned to treatment by chance), single-blind (with respect to dose), open-label (patients know what study treatment, not dose, they are receiving) repeated dose study evaluating patients with chronic cancer pain was conducted in tandem (together) with a similar protocol in patients with chronic non-malignant pain. A total of 463 patients were enrolled and evaluated in these studies. Patients receiving chronic opioid therapy were converted to once daily OROS hydromorphone (slow release) using oral morphine equivalents. Supplementary immediate-release (IR) hydromorphone was provided for breakthrough pain. The dose of OROS hydromorphone (slow release) was escalated after every 2 days of therapy until no more than 3 doses of immediate-release (IR) hydromorphone were required in a 24-hour period. Once a patient could be maintained on a stable dose of OROS hydromorphone (slow release) for 3 consecutive days, the patient entered a 2-week maintenance phase. Patients who completed the study were eligible for participation in an OROS hydromorphone (slow release) long-term extension study, Study DO-109. The hypothesis is the 24-hour controlled-release form of oral hydromorphone may provide consistent pain relief, convenient dosing, and enhanced compliance while possibly decreasing the incidence of side effects associated with peak (high) and trough (low) fluctuations in plasma drug concentrations typically seen with immediate-release dosage formulations. Patients received OROS Hydromorphone HCI (slow release) at Visit 2,3, and 4 (either 8,16,32, and/or 64mg tablets) taken orally. OROS Hydromorphone HCI (slow release) doses were titrated after every two days of therapy as necessary until dose stabilization occured, followed by a two week Maintenance Therapy Phase.
Disclosed are compounds having the following formula: wherein R is an alkane chain having between 8 and 20 carbon atoms, and A is one or more anions having a total charge of -2; or R is a quaternary amine having the following formula: wherein Ra and Rb are each an alkane chain having between 8 and 20 carbon atoms, and A is one or more anions having a total charge of -3. Methods for making the compounds are also claimed. In a preferred embodiment, R is an alkane chain of 10 atoms and A is two chloride ions. In another embodiment, Ra and R b are both alkane chains 10 carbon atoms in length and A is ions and a bromide ion. The compositions of the invention may be used in the treatment of fungal, bacterial and viral infections. In preferred embodiments the composition is used to treat the herpes virus or the human papilloma virus.
1312233 Preparing 3-methyl-cephalosporanic acid esters GLAXO LABORATORIES Ltd 10 March 1970 [5 Dec 1969] 59450/69 Heading C2A 7# - Acylamido - 3 - methyl - cephalosporanic acid esters are prepared by heating a 6#-acylamido penicillanic acid 1-oxide ester in the presence of a catalyst comprising a mono-O- substituted orthophosphoric acid, an O,O-di- (aryl substituted) orthophosphoric acid, or a salt of an amine base of pKb not less than 4 with one of the said acids (which salt may be formed in situ in the reaction mixture) or two or more of the said catalysts. Mono-O-substituted orthophosphoric acids may be aliphatic, araliphatic or aryl dihydrogen phosphates, of which the hydrocarbyl groups may be substituted, e.g. phenyl-, p-nitrophenyl-, 2-chloromethyl-4-nitrophenyl-, and 2,2,2-trichloroethylhydrogen phosphate. Typical O,O-di(aryl substituted) orthophosphoric acids have phenyl or phenyl substituted by one or more halogen or nitro groups, e.g. bis- (4-nitrophenyl) hydrogen phosphate. The amine base may be organic or inorganic, e.g. pyridine, quinoline, picoline, isoquinoline, benzimidazole, and 2- and 4-methyl-quinoline, and such bases substituted by, e.g. halogen, acyl, acylamido, cyano, carboxy or aldoximino groups; also aniline optionally substituted by halogen (e.g. chlorine), alkyl, hydroxy, alkoxy, nitro, carboxy or N-alkyl may be used. When the base is used as a phosphoric acid salt, either the base or the acid may be present in excess of the equivalent amount. A preferred salt is pyridinium 2,2,2 - trichloroethyl dihydrogen phosphate. The reaction is preferably conducted in one of the solvents used in the process of Specification 1,299,734, the processes used to isolate the product and the oxidation procedure for preparing the penicillin 1-oxide are also as described in the said Specification.
One of the greatest difficulties encountered in the treatment of Chagas disease by chemotherapy is the natural resistance of  T. cruzi  to the pharmaceuticals available, and also the fact that parasites that are resistant to a certain compound are also resistant to other compounds. The same occurs in the treatment of cancer, where resistance to chemotherapeutic agents is daily increasing. The aim of the present invention is to provide substances having pharmacological activity and effectiveness for use as a pharmaceutical product for humans and animals, and useful for treating diseases caused by naturally resistant parasites, in particular  T. cruzi  and other parasites, such as those belonging to Leishmania species, and also for the treatment of cancer. The activity of furan heliangolide sesquiterpenoid compounds has been clearly verified  in vivo  and  in vitro , in particular that of licnofolide (1), the NC-LIC presenting the best results (P < 0.005) for the treatment of infection by  T. cruzi  of mice infected with all the strains studied, including animals infected with the Colombian strain, which is 100% resistant to BZ, both with regard to parasitemia (CL, Y and Colombian strains) and survival of the animals (CL, Y and Colombian strains). Free lactone (free LIC9) also showed partial results for both parameters (parasitemia and survival). This confirms the previously studied activity of this lactone  in vitro  (Oliveira et al., Phytotherapy Research, 10(4), 292-295, 1996) and constitutes the first evidence of the potential of this substance for the treatment  in vivo  of parasite samples with different resistance or sensitivity profiles to drugs conventionally used for the treatment of human Chagas disease (benznidazole and nifurtimox). It was also demonstrated that the best results were observed with a formulation contained in polymeric nanocapsules obtained from PCL polymers and also from polylactic acid covalently bonded to polyethyleneglycol, the so-called stealth nanocapsules, which were described for the first time by Mosqueira et alia (Mosqueira et alia, Journal of Drug Targeting, vol. 7, no. 1, pages 65-78, 1999).
Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m\^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m\^3 pentostatin IV over 30 minutes and 600 mg/m\^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.) was dissolved in 50mL normal saline or glucose and perfused into the bladder for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery.
A compound tuber onion seed oil health-care spray and a preparing method are provided. Tuber onion seed oil, propolis, maca seed oil and ginseng flower volatile oil are natural medicinal and edible materials and are prepared into the oral spray by a conventional oral spray preparing manner through adding auxiliary materials. The tuber onion seed oil, the propolis, the maca seed oil and the ginseng flower volatile oil are natural medicinal and edible materials, and synergistic effects of the medicinal and edible materials are utilized. Selected medicines are natural plant medicines and are scientific in compatibility, and have obvious synergistic effects. A preparing process is reasonable. Effective components of the traditional Chinese medicine raw materials are not destroyed. The spray is free of toxic or side effect, free of addiction and free of drug resistance, and is capable of promoting blood circulation and metabolism, boosting human immunity, relieving fatigue, rapidly restoring strength and vigor, and tonifying Yang. The spray can be prepared into proper preparation forms, is suitable for daily taking as a healthcare product for human and has a good market prospect.
Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
CDKL5 deficiency disorder (CDD) is an X-linked dominant epileptic encephalopathy, characterized by early-onset and drug-resistant seizures, psychomotor delay, and slight facial features. Genomic variants inactivating CDKL5 or impairing its protein product kinase activity have been reported, making next-generation sequencing (NGS) and chromosomal microarray analysis (CMA) the standard diagnostic tests. We report a suspicious case of CDD in a female child who tested negative upon NGS and CMA and harbored an X chromosome de novo pericentric inversion. The use of recently developed genomic techniques (optical genome mapping and whole-genome sequencing) allowed us to finely characterize the breakpoints, with one of them interrupting CDKL5 at intron 1. This is the fifth case of CDD reported in the scientific literature harboring a structural rearrangement on the X chromosome, providing evidence for the hypothesis that this type of anomaly can represent a recurrent pathogenic mechanism, whose frequency is likely underestimated, with it being overlooked by standard techniques. The identification of the molecular etiology of the disorder is extremely important in evaluating the pathological outcome and to better investigate the mechanisms associated with drug resistance, paving the way for the development of specific therapies. Karyotype and genomic techniques should be considered in all cases presenting with CDD without molecular confirmation.
Compounds of formula (I) or salts thereof are provided wherein X is O or S, A and B are OR2 or Y—NR3R4 wherein when A is OR2. B is Y—NR3R4 and vice versa, or when one of A or B is OR2. then the other can be CO 2 R7. Y is CH 2  or C═Q. Q is (CH 2 ) m —CH(R1)—(CH 2 ) n , R is OR6 or NHR7. and with the other definitions as set out in claim 1, a process for its preparation and its use in the prophylaxis or treatment of fungal infections.
Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention describes bicyclic derivatives of amidine of the formula (I)   where D means five-membered heterocyclic aromatic ring containing from 1 to 4 heteroatoms taken among O, N or S and optionally substituted by carbon atom with halogen atom, trifluoromethyl, C 1-6 -alkyl, nitro- or cyano-group and bound with other moiety of compound of the formula (I) through carbon atom; A means N(X) or CH (-(CH 2 ) m -NXY); U means NH, O or CH 2 ; V means (CH 2 ) a ; W means (CH 2 ) b ; a, b, m, X and Y have values given in the invention claim. Invention describes also methods of synthesis of compounds and preparing the pharmaceutical composition containing thereof. Compounds of the formula (I) are inhibitors of nitrogen oxide synthetase activity and can be used in therapy. EFFECT: improved method of synthesis, valuable biochemical and therapeutic properties of compounds. 10 cl